Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR
Authors:
- 1 June 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 7 (6) , 989-1002
Abstract
Summary: Background and objectives: CKD is common among older patients. This article assesses long-term renal and cardiovascular outcomes in older high-risk hypertensive patients, stratified by baseline estimated GFR (eGFR), and long-term outcome efficacy of 5-year first-step treatment with amlodipine or lisinopril, each compared with chlorthalidone. Design, setting, participants, & measurements: This was a long-term post-trial follow-up of hypertensive participants (n=31,350), aged ≥55 years, randomized to receive chlorthalidone, amlodipine, or lisinopril for 4–8 years at 593 centers. Participants were stratified by baseline eGFR (ml/min per 1.73 m2) as follows: normal/increased (≥90; n=8027), mild reduction (60–89; n=17,778), and moderate/severe reduction (n=5545). Outcomes were cardiovascular mortality (primary outcome), total mortality, coronary heart disease, cardiovascular disease, stroke, heart failure, and ESRD. Results: After an average 8.8-year follow-up, total mortality was significantly higher in participants with moderate/severe eGFR reduction compared with those with normal and mildly reduced eGFR (PP=0.64), or chlorthalidone and lisinopril (P=0.56). Likewise, no significant differences were observed for total mortality, coronary heart disease, cardiovascular disease, stroke, or ESRD. Conclusions: CKD is associated with significantly higher long-term risk of cardiovascular events and mortality in older hypertensive patients. By eGFR stratum, 5-year treatment with amlodipine or lisinopril was not superior to chlorthalidone in preventing cardiovascular events, mortality, or ESRD during 9-year follow-up. Because data on proteinuria were not available, these findings may not be extrapolated to proteinuric CKD.Keywords
This publication has 36 references indexed in Scilit:
- Intensive Blood-Pressure Control in Hypertensive Chronic Kidney DiseaseNew England Journal of Medicine, 2010
- Comparative Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study Equations for Estimating GFR Levels Above 60 mL/min/1.73 m2American Journal of Kidney Diseases, 2010
- Chronic kidney disease increases cardiovascular unfavourable outcomes in outpatients with heart failureBMC Nephrology, 2009
- Should diuretics always be included as initial antihypertensive management in early-stage CKD?Current Opinion in Nephrology and Hypertension, 2009
- Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure LoweringJournal of the American Society of Nephrology, 2007
- Effects of calcium channel blockers on “dynamic” and “steady-state step” renal autoregulationAmerican Journal of Physiology-Renal Physiology, 2004
- Kidney Disease as a Risk Factor for Development of Cardiovascular DiseaseHypertension, 2003
- The Chronic Renal Insufficiency Cohort (CRIC) StudyJournal of the American Society of Nephrology, 2003
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Effects of amlodipine on renal hemodynamicsThe American Journal of Cardiology, 1989